Safinamide is filed at FDA as add on therapy for Parkinsons disease - Newron + Zambon

Newron Pharmaceuticals SpA and its partner Zambon SpA announce that a new drug application for safinamide was submitted to the FDA. The submission covers the indications of safinamide as add on therapy to a stable dose of a single dopamine agonist in early Parkinsons disease patients and as add on therapy to levodopa alone or in combination with other Parkinsons disease treatments in mid to late stage Parkinsons disease patients. Zambon SpA will market the drug in the USA.